Cargando…

Association of NEDA-4 With No Long-term Disability Progression in Multiple Sclerosis and Comparison With NEDA-3: A Systematic Review and Meta-analysis

BACKGROUND AND OBJECTIVES: No evidence of disease activity (NEDA)-4 has been suggested as a treatment target for disease-modifying therapy (DMT) in relapsing-remitting multiple sclerosis (RRMS). However, the ability of NEDA-4 to discriminate long-term outcomes in MS and how its performance compares...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rotstein, Dalia, Solomon, Jacqueline M., Sormani, Maria Pia, Montalban, Xavier, Ye, Xiang Y., Dababneh, Dina, Muccilli, Alexandra, Saab, Georges, Shah, Prakesh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9558627/ https://www.ncbi.nlm.nih.gov/pubmed/36224046 http://dx.doi.org/10.1212/NXI.0000000000200032

Ejemplares similares

NEDA—NEutron Detector Array
por: Valiente-Dobón, J J, et al.
Publicado: (2019)

No Evidence of Disease Activity (NEDA) in Multiple Sclerosis - Shifting the Goal Posts
por: Pandit, Lekha
Publicado: (2019)

Prognostic Accuracy of NEDA-3 in Long-term Outcomes of Multiple Sclerosis
por: Prosperini, Luca, et al.
Publicado: (2021)

aHSCT is superior to alemtuzumab in maintaining NEDA and improving cognition in multiple sclerosis
por: Häußler, Vivien, et al.
Publicado: (2021)

Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis
por: Kappos, Ludwig, et al.
Publicado: (2015)

Evidence of disease control: a realistic concept beyond NEDA in the treatment of multiple sclerosis
por: Londoño, Ana C., et al.
Publicado: (2017)

Thalamic Atrophy Without Whole Brain Atrophy Is Associated With Absence of 2-Year NEDA in Multiple Sclerosis
por: Hänninen, Katariina, et al.
Publicado: (2019)

The New Neutron Multiplicity Filter NEDA and Its First Physics Campaign with AGATA
por: Jaworski, G, et al.
Publicado: (2019)

Effectiveness of teriflunomide on No Evidence of Disease Activity and cognition in relapsing remitting multiple sclerosis: results of the NEDA3PLUS study
por: Amato, Maria Pia, et al.
Publicado: (2023)

NEDA-3 status including cortical lesions in the comparative evaluation of natalizumab versus fingolimod efficacy in multiple sclerosis
por: Puthenparampil, Marco, et al.
Publicado: (2018)

A Preliminary Study on the Meaning of Inflammatory Indexes in MS: A Neda-Based Approach
por: Bunul, Sena Destan, et al.
Publicado: (2023)

Clinical predictors of NEDA-3 one year after diagnosis of pediatric multiple sclerosis: an exploratory single-center study
por: Palavra, Filipe, et al.
Publicado: (2023)

No Evidence of Disease Activity (NEDA) as a Clinical Assessment Tool for Multiple Sclerosis: Clinician and Patient Perspectives [Narrative Review]
por: Newsome, Scott D., et al.
Publicado: (2023)

Diastolic dysfunction and mortality in 436 360 men and women: the National Echo Database Australia (NEDA)
por: Playford, David, et al.
Publicado: (2020)

Long-term evaluation of NEDA-3 status in relapsing-remitting multiple sclerosis patients after switching from natalizumab to fingolimod
por: Diem, Lara, et al.
Publicado: (2018)

miRNA 548a-3p as biomarker of NEDA-3 at 2 years in multiple sclerosis patients treated with fingolimod
por: Gonzalez-Martinez, Alicia, et al.
Publicado: (2023)

Increased Within-Network Functional Connectivity May Predict NEDA Status in Fingolimod-Treated MS Patients
por: Piervincenzi, Claudia, et al.
Publicado: (2021)

No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a
por: Havrdová, Eva, et al.
Publicado: (2018)

Rebaseline no evidence of disease activity (NEDA-3) as a predictor of long-term disease course in a Norwegian multiple sclerosis population
por: Simonsen, Cecilia Smith, et al.
Publicado: (2022)

VEP Score of a Left Eye Had Predictive Values for Achieving NEDA-3 over Ten Years in Patients with Multiple Sclerosis
por: Miletic-Drakulic, Svetlana, et al.
Publicado: (2022)

Effectiveness of Natalizumab in Achieving No Evidence of Disease Activity (NEDA-3)—Data From a Local Norwegian Cohort
por: Jaklin, Andreas K., et al.
Publicado: (2021)

Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study
por: Giovannoni, Gavin, et al.
Publicado: (2021)

George N. Papanicolaou (1883–1962), an exceptional human, scientist and academic teacher: An interview with Dr Neda Voutsa-Perdiki
por: Mammas, Ioannis N., et al.
Publicado: (2017)

Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years
por: Guerra, Tommaso, et al.
Publicado: (2021)

The Comparative Efficacy of Non-ergot Dopamine Agonist and Potential Risk Factors for Motor Complications and Side Effects From NEDA Use in Early Parkinson's Disease: Evidence From Clinical Trials
por: Wu, Chunxiao, et al.
Publicado: (2022)

Clinical characteristics and outcomes of multiple sclerosis patients with COVID-19 in Toronto, Canada
por: Solomon, Jacqueline M., et al.
Publicado: (2022)

Chronic Cognitive Impairment in AQP4+ NMOSD With Improvement in Cognition on Eculizumab: A Report of Two Cases
por: Saab, Georges, et al.
Publicado: (2022)

Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study
por: Miller, David H., et al.
Publicado: (2018)

Estimating individual treatment effect on disability progression in multiple sclerosis using deep learning
por: Falet, Jean-Pierre R., et al.
Publicado: (2022)

Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets
por: De Stefano, Nicola, et al.
Publicado: (2017)

An Italian programme for COVID-19 infection in multiple sclerosis
por: Sormani, Maria Pia
Publicado: (2020)

Confirmed disability progression as a marker of permanent disability in multiple sclerosis
por: Sharmin, Sifat, et al.
Publicado: (2022)

Learning ability correlates with brain atrophy and disability progression in RRMS
por: Sormani, Maria Pia, et al.
Publicado: (2019)

CSF Chitinase 3–Like 2 Is Associated With Long-term Disability Progression in Patients With Progressive Multiple Sclerosis
por: Comabella, Manuel, et al.
Publicado: (2021)

Evidence for a two-stage disability progression in multiple sclerosis
por: Leray, Emmanuelle, et al.
Publicado: (2010)

Cerebellar volume as imaging outcome in progressive multiple sclerosis
por: Inglese, Matilde, et al.
Publicado: (2017)

Recurrent disability progression endpoints in multiple sclerosis clinical trials
por: Bühler, Alexandra, et al.
Publicado: (2022)

Gray Matter Correlates of Cognitive Performance Differ between Relapsing-Remitting and Primary-Progressive Multiple Sclerosis
por: Jonkman, Laura E., et al.
Publicado: (2015)

A window into the future? MRI for evaluation of neuromyelitis optica spectrum disorder throughout the disease course
por: Solomon, Jacqueline M., et al.
Publicado: (2021)

Therapeutic Inertia in the New Landscape of Multiple Sclerosis Care
por: Saposnik, Gustavo, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_hj4m61a1e8q7bjdtjl3vej3rda